OBJECTIVES:: Evaluate effect of baricitinib (BARI) on work productivity in Latin American (LA)* patients with moderately to severely active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX). *LA countries: Argentina and Mexico. METHODS:: In the double-blind RA-BEAM study, 1305 patients with active RA on established methotrexate treatment were randomized in 3:3:2 to receive 4 mg BARI orally once daily, 40 mg adalimumab (ADA) subcutaneously once every 2 weeks, or matching placebo (PBO) for up to 52 weeks; the latter were switched to BARI at Week 24. Rescue treatment was offered to all nonresponders from Week 16/subsequent visits. Work productivity was assessed using Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) at Week 4 and every 4 weeks thereafter. Treatment differences were compared using ANCOVA after adjusting baseline, baseline joint erosion status (1-2 erosions plus seropositivity, ≥3 erosions) and treatment group. Data from LA subgroup (N=380) of patients are presented here. RESULTS::  Among the 380 randomized LA patients (143 BARI, 96 ADA, and 141 PBO), 35% on BARI, 32% on ADA, and 38% on PBO were employed at baseline. Significant (p<0.05) improvement was observed in patients receiving BARI at Week 24 when compared to PBO but not to ADA with respect to presenteeism (mean change: -25, -10 and -20), activity impairment (mean change: -34, -18 and -30), and productivity loss (mean change: -27.4 -4.1 and -19.9). Significant improvement was observed in patients receiving BARI compared to ADA at Week 52 in presenteeism (mean change: -27 vs. -22) and productivity loss (mean change: -31.6 vs.-18.8). CONCLUSIONS::  Significant improvements in most work productivity scores were observed for BARI in comparison to PBO and ADA at different time points in this subgroup analysis of LA patients with moderate to severe RA. The results from this subgroup of LA patients are consistent to those observed in the global RA-BEAM study.